Ultromics Secures $55M to Revolutionize Heart Disease Diagnosis with AI
July 31, 2025, 9:36 pm
Location: United Kingdom, England, Oxford
Employees: 51-200
Founded date: 2015
Ultromics, a leader in AI-driven cardiology, secured $55 million in Series C funding. This significant investment propels its mission to transform heart disease diagnosis. The company's EchoGo® platform utilizes advanced AI. It analyzes standard echocardiograms. This technology detects complex and often missed heart conditions. Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis are key targets. These conditions pose significant diagnostic challenges. Ultromics' solution improves accuracy and speed. It integrates seamlessly into existing clinical workflows. The platform is FDA-cleared. It also holds Medicare reimbursement. This ensures broad accessibility in the United States.
The funding round saw strong participation. L&G, Allegis Capital, and Lightrock co-led the investment. Existing supporters like Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University reaffirmed their commitment. Major US health systems also joined. UChicago Medicine’s UCM Ventures and UPMC Enterprises invested. This underscores growing confidence in Ultromics' technology. These funds will drive extensive expansion. They will boost research and development efforts. The focus remains on scaling US operations.
Heart disease remains a global health crisis. Early, accurate diagnosis is crucial. Traditional diagnostic methods often fall short. They can be subjective. They may lead to delayed or missed diagnoses. This is especially true for elusive conditions. HFpEF affects millions. Up to 64 percent of cases go undiagnosed. Cardiac amyloidosis is another challenge. It is frequently misidentified. Patients often remain untreated. Their symptoms worsen. These diagnostic gaps create critical patient care issues.
Ultromics tackles this pervasive problem directly. Its EchoGo® platform changes the paradigm. It uses artificial intelligence to find subtle disease signals. These signals are hidden within routine echocardiograms. The platform provides real-time probability scores. Cardiologists gain vital insights. They can identify high-risk patients much sooner. This enables earlier intervention. It prevents disease progression. The technology requires no new hardware. It integrates smoothly into clinical settings.
Clinical studies validate EchoGo®'s power. Ultromics has analyzed over 430,000 echocardiograms. This vast dataset fuels its AI models. In trials, EchoGo® significantly improved HFpEF detection. It showed a 73.6 percent improvement. This compares favorably to standard clinical risk scores. The company’s latest diagnostic model focuses on cardiac amyloidosis. A global study across 18 institutions validated it. The model outperformed existing risk scores. It accurately distinguished cardiac amyloidosis from similar conditions.
The US market is a strategic priority. Ultromics has significantly strengthened its presence there. The company boasts critical partnerships. Collaborations include the University of Chicago Medicine, University Hospitals Cleveland, and Mayo Clinic. These alliances are building regional clinical and commercial strongholds. The Midwest, a high-prevalence region for heart disease, is a key focus. This localized strategy aims for widespread adoption.
Ultromics has achieved important regulatory milestones. In late 2024, EchoGo® Amyloidosis received FDA Breakthrough Device clearance. This recognition highlights its innovative potential. It underscores the unmet need it addresses. In 2025, Ultromics launched EchoGo® Score. This tool further enhances HFpEF detection. Crucially, Medicare reimbursement is now in place. It covers both outpatient and inpatient use. This opens doors for scaled adoption across US hospitals.
Hospitals benefit in multiple ways. The platform reduces unnecessary tests. It streamlines workflows. It enables earlier treatment initiation. This approach enhances medical intervention effectiveness. It also contributes to cost reduction. Healthcare systems seek scalable solutions. They need improved early and accurate diagnosis. Ultromics provides this answer. Its technology supports clinical decisions. It expands access to specialist care.
The newly acquired funds will fuel aggressive expansion. Ultromics will broaden its reach in the US. It will target other priority markets. Hospitals and echo labs are key. These facilities handle large volumes of at-risk patients. The goal is clear. AI-powered diagnostics must become a standard part of cardiac assessments. This ensures more patients receive timely, accurate diagnoses.
Product pipeline expansion is also a focus. Ultromics aims to cover more cardiac conditions. Broadening distribution channels is vital. Strengthening collaborations with health systems and clinical experts continues. This multi-faceted approach ensures sustained growth. It drives continuous innovation. The company remains committed to transforming cardiovascular care. Ultromics' AI technology is a vital step forward. It brings advanced diagnostics to the forefront. It ultimately helps save lives.
The funding round saw strong participation. L&G, Allegis Capital, and Lightrock co-led the investment. Existing supporters like Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University reaffirmed their commitment. Major US health systems also joined. UChicago Medicine’s UCM Ventures and UPMC Enterprises invested. This underscores growing confidence in Ultromics' technology. These funds will drive extensive expansion. They will boost research and development efforts. The focus remains on scaling US operations.
Heart disease remains a global health crisis. Early, accurate diagnosis is crucial. Traditional diagnostic methods often fall short. They can be subjective. They may lead to delayed or missed diagnoses. This is especially true for elusive conditions. HFpEF affects millions. Up to 64 percent of cases go undiagnosed. Cardiac amyloidosis is another challenge. It is frequently misidentified. Patients often remain untreated. Their symptoms worsen. These diagnostic gaps create critical patient care issues.
Ultromics tackles this pervasive problem directly. Its EchoGo® platform changes the paradigm. It uses artificial intelligence to find subtle disease signals. These signals are hidden within routine echocardiograms. The platform provides real-time probability scores. Cardiologists gain vital insights. They can identify high-risk patients much sooner. This enables earlier intervention. It prevents disease progression. The technology requires no new hardware. It integrates smoothly into clinical settings.
Clinical studies validate EchoGo®'s power. Ultromics has analyzed over 430,000 echocardiograms. This vast dataset fuels its AI models. In trials, EchoGo® significantly improved HFpEF detection. It showed a 73.6 percent improvement. This compares favorably to standard clinical risk scores. The company’s latest diagnostic model focuses on cardiac amyloidosis. A global study across 18 institutions validated it. The model outperformed existing risk scores. It accurately distinguished cardiac amyloidosis from similar conditions.
The US market is a strategic priority. Ultromics has significantly strengthened its presence there. The company boasts critical partnerships. Collaborations include the University of Chicago Medicine, University Hospitals Cleveland, and Mayo Clinic. These alliances are building regional clinical and commercial strongholds. The Midwest, a high-prevalence region for heart disease, is a key focus. This localized strategy aims for widespread adoption.
Ultromics has achieved important regulatory milestones. In late 2024, EchoGo® Amyloidosis received FDA Breakthrough Device clearance. This recognition highlights its innovative potential. It underscores the unmet need it addresses. In 2025, Ultromics launched EchoGo® Score. This tool further enhances HFpEF detection. Crucially, Medicare reimbursement is now in place. It covers both outpatient and inpatient use. This opens doors for scaled adoption across US hospitals.
Hospitals benefit in multiple ways. The platform reduces unnecessary tests. It streamlines workflows. It enables earlier treatment initiation. This approach enhances medical intervention effectiveness. It also contributes to cost reduction. Healthcare systems seek scalable solutions. They need improved early and accurate diagnosis. Ultromics provides this answer. Its technology supports clinical decisions. It expands access to specialist care.
The newly acquired funds will fuel aggressive expansion. Ultromics will broaden its reach in the US. It will target other priority markets. Hospitals and echo labs are key. These facilities handle large volumes of at-risk patients. The goal is clear. AI-powered diagnostics must become a standard part of cardiac assessments. This ensures more patients receive timely, accurate diagnoses.
Product pipeline expansion is also a focus. Ultromics aims to cover more cardiac conditions. Broadening distribution channels is vital. Strengthening collaborations with health systems and clinical experts continues. This multi-faceted approach ensures sustained growth. It drives continuous innovation. The company remains committed to transforming cardiovascular care. Ultromics' AI technology is a vital step forward. It brings advanced diagnostics to the forefront. It ultimately helps save lives.